Erkut Bahceci

Hematology
300 George St Fl 6
New Haven, CT 06511

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.

Journal: Blood advances
Published: October 29, 2021

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.

Journal: Clinical pharmacokinetics
Published: July 23, 2021

Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.

Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.

Journal: Drugs in R&D
Published: November 20, 2020

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.

Journal: Clinical pharmacokinetics
Published: April 19, 2020

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.

Journal: Cancer medicine
Published: April 01, 2020

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Journal: The New England journal of medicine
Published: October 31, 2019

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Journal: Blood advances
Published: August 30, 2019

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.

Journal: Cancer science
Published: March 22, 2018

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

Journal: Blood advances
Published: January 08, 2018

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Journal: The Lancet. Oncology
Published: February 09, 2017

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Journal: Journal of hematology & oncology
Published: February 18, 2016

The Patient Perspective on Living with Acute Myeloid Leukemia.

The Patient Perspective on Living with Acute Myeloid Leukemia.

Journal: Oncology and therapy
Published: January 01, 2016
Showing 1-12 of 12

Last Updated: 09/26/2026